Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic Oncology, Synthetic Lethality, and Resistance Profiling.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PRMT5 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Target Protein (WT & Mutant) | PRMT5 Recombinant Protein (Full-Length & Catalytic Domain) and PRMT5/MEP50 Complex. High purity (>95%), Endotoxin <1 EU/µg. Sequence verified. Includes resistance mutants G63A, M276I, F327L, Y328H. | View PRMT5 Products |
| Co-factor Partner / Regulatory Subunit | WDR77 (MEP50) Recombinant Protein. HEK293 expressed. Essential for PRMT5 holoenzyme reconstitution. | View WDR77 Products |
| Gene Delivery | PRMT5 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction and target engagement studies. MTAP-null compatible. | View PRMT5 Products |
| Benchmark Antibody | Anti-PRMT5 Recombinant Antibody, sequence-verified positive control for Western blot, IP, and cellular degradation assays. | View PRMT5 Products |
| Validator | PRMT5 siRNA Set. For knockdown verification and rescue experiments. Sequence verified. | View PRMT5 Products |
| Synthetic Lethal Partner | MTAP Recombinant Protein. For MTAP-deletion biomarker studies and rescue experiments. >95% purity. | View MTAP Products |
| Related Target A | MTAP – Synthetic lethality biomarker; MTAP deletion defines responsive patient population for MTA-cooperative inhibitors. | View MTAP Products |
| Related Target B | MAT2A – Synergistic pathway target for SAM modulation in MTAP-deleted cells; combination therapy validation. | View MAT2A Products |
| Related Target C | PRMT1 – Key paralog for methyltransferase selectivity counter-screening and off-target liability assessment. | View PRMT1 Products |
| Related Target D | CARM1/PRMT4 – Type I arginine methyltransferase for broader selectivity profiling and combinatorial strategy. | View CARM1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Catalytic Holoenzyme Reconstitution | PRMT5 + WDR77/MEP50 co-available; HEK293 expressed with mammalian folding. Purity >95% by SDS-PAGE. |
| MTA-Cooperative Inhibitor Selectivity | PRMT5 WT recombinant protein for differential enzymatic inhibition in presence of MTA vs SAH. |
| Resistance Mutation Profiling (G63A, M276I, F327L, Y328H) | Sequence-verified mutant proteins with >95% purity; theoretical MW confirmed by mass spec. |
| Selectivity vs PRMT Family (PRMT1, PRMT3, CARM1) | Human paralog panel strictly sequence verified; high-purity >95% for high-throughput screening. |
| MTAP Synthetic Lethal Validation | MTAP recombinant protein and PRMT5 lentivirus available for rescue experiments in MTAP-null cells. |
| Cell-based Target Engagement & Genetic Rescue | Lentivirus-based stable overexpression lines and validated siRNA for specificity confirmation. |
| False Positives in Biochemical Screens | Validated siRNA included for genetic knockdown confirmation; rescue constructs available. |
| Lack of Validated Controls | Clinical benchmark references (e.g., GSK3326595, LLY-283) included for reliable baseline calibration. |
Live PRMT5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PRMT5 therapeutics is intensifying, with major players shifting focus from first-generation active-site inhibitors to next-generation MTA-cooperative inhibitors and PROTAC degraders. First-generation agents (e.g., GSK3326595, LLY-283, AZD3470) established proof-of-concept in hematological malignancies but faced dose-limiting toxicities. The next wave of R&D is explicitly targeting MTAP-deleted solid tumors (~15% of all cancers) through synthetic lethality, offering a dramatically improved therapeutic window. Key players include Amgen (AMG 193), Mirati/BMS (MRTX1719), and Tango Therapeutics (TNG462). Emerging modalities include brain-penetrant compounds for glioblastoma, allosteric inhibitors disrupting the PRMT5-MEP50 interface, and PROTAC degraders to overcome resistance. Resistance mutations (e.g., G63A, M276I, F327L) are driving the need for pre-emptive screening tools.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| 1st-Gen Small Molecule (Active Site / Allosteric) | GSK, Eli Lilly, AstraZeneca, Johnson & Johnson | Myeloid malignancies (MDS, AML, MF), solid tumors | General enzymatic inhibition assay; need PRMT5/WDR77 holoenzyme complex (>95% purity) |
| Next-Gen MTA-Cooperative Inhibitor | Amgen, Mirati (BMS), Tango Therapeutics, Johnson & Johnson | MTAP-deleted solid tumors (NSCLC, pancreatic, mesothelioma) | Differential cofactor assay (PRMT5 with MTA vs SAH); MTAP protein for synthetic lethal validation |
| PROTAC / Degrader | Emerging biotech and academic groups | Refractory solid tumors | High-purity PRMT5 for ternary complex formation assays; benchmark antibody for degradation readout |
| Brain-Penetrant Inhibitor | Preclinical stage | Glioblastoma, brain metastases | Cell-based permeability assays using stable PRMT5-overexpressing lines |
| Combination Therapy (e.g., with MAT2A inhibitor) | Ideaya Biosciences | MTAP-deleted cancers | Synergy validation; need MAT2A and PRMT5 active proteins |
Conclusion
Next-generation PRMT5 drug development demands rigorous selectivity profiling against the broader PRMT family (PRMT1, PRMT3, CARM1), resistance mutation coverage, and MTAP synthetic lethality validation. TarMart provides the sequence-verified protein panel, holoenzyme complexes, and validated tools necessary to meet these critical assay needs.